XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the integration of 3a-diagnostics GmbH (“3a”) into XPhyto’s German operations. According to the update, the acquisition of 3a, announced Dec. 6, 2021, is a primary driver of XPhyto’s recent management activities in Germany. The company has worked diligently to expedite the launch of its COVID-ID lab test system, a flexible and rapid 20 minute-RT-PCR test, into the European market. The company is facilitating sales activities inside and outside Germany and is continuing with other EU countries as COVID-ID lab can be distributed in all countries that accept an EU CE mark. It was critical that 3a diagnostics be integrated into the company as a prerequisite. This was quickly achieved by joining forces between 3a and Vektor Pharma TF GmbH, the two German science-based companies in the XPhyto portfolio. “We are now realizing significant synergies in research and development, commercialization, marketing and sales, as well as significantly improved margins for commercial products, particularly Covid-ID Lab,” said Prof. Dr. Thomas Beckert, managing director. “Vektor’s qualified personnel has now assumed training, customer support and product distribution activities from 3a, which permits 3a to focus on the development of new diagnostic products. Our next step in management optimization is the implementation of project management excellence across all product development programs, from research and development to sales and distribution.”
To view the full press release, visit https://ibn.fm/RDh0L
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. To learn more, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.